Icalziss

Calcium chloride dihydrate, the active ingredient in Icalziss, is an electrolyte supplement presented as a solution for extracorporeal use. It provides calcium ions to support electrolyte balance and physiological functions in patients requiring intravenous calcium replacement.

GNH USA supplies Icalziss as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide. The company adheres to strict quality standards and provides regulatory documentation for importers and health‑care institutions across multiple regions. Products are shipped under controlled conditions to ensure stability and compliance with EU pharmacopeial specifications.

Icalziss (calcium chloride dihydrate) is used to restore calcium levels in clinical situations involving electrolyte imbalance. - Hypocalcemia: restores serum calcium concentrations in patients with acute or chronic low calcium levels. - Parenteral nutrition: supplies calcium as an essential mineral in total parenteral nutrition admixtures. - Hemodialysis: provides calcium in dialysis solutions to maintain calcium balance during extracorporeal treatment. - Cardiac arrest support: delivers calcium ions during resuscitation to assist myocardial contractility.

Calcium chloride dihydrate may be associated with several adverse reactions, ranging from mild to severe.

Common Side Effects: - Irritation at infusion site: redness, pain, or swelling where the solution is administered. - Hypercalcemia: transient elevation of serum calcium causing mild nausea or fatigue. - Nausea or vomiting: gastrointestinal discomfort following rapid infusion. - Hypotension: drop in blood pressure during or shortly after administration.

Serious or Rare Side Effects: - Cardiac arrhythmia: abnormal heart rhythms, especially in patients with underlying heart disease. - Severe hypercalcemia: can lead to confusion, renal impairment, or calcification of tissues. - Tissue necrosis: extravasation of the solution may cause local tissue damage. - Anaphylactic reaction: rare severe allergic response requiring immediate medical intervention.

When using Icalziss, several precautions should be observed to minimize risks and ensure safe administration. - Monitor serum calcium: check calcium levels before, during, and after infusion to avoid over‑correction. - Assess renal function: impaired kidneys may reduce calcium clearance and increase toxicity risk. - Infuse slowly: rapid administration can cause cardiovascular instability and local irritation. - Review cardiac history: patients with arrhythmias or myocardial ischemia require careful monitoring. - Check compatibility: ensure the solution is compatible with other IV fluids and medications before mixing. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Calcium chloride dihydrate can interact with certain medicines, affecting their efficacy or safety.

Major Interactions (Avoid): - Bisphosphonates: concurrent IV calcium may reduce the anti‑resorptive effect of bisphosphonates. - Calcium channel blockers: high calcium levels can diminish the hypotensive action of these agents. - Potassium chloride solutions: mixing can cause precipitation and catheter blockage.

Moderate Interactions (Monitor Closely): - Loop diuretics: increase calcium excretion, requiring closer monitoring of calcium levels. - Digitalis glycosides: elevated calcium may enhance digitalis toxicity. - Magnesium sulfate: concurrent administration can lead to electrolyte imbalance; monitor both ions. - Phosphate binders: calcium may bind phosphate, altering phosphate control in renal patients.